Abstract
Naoxintong (NXT), a Chinese Materia Medica standardized product, extracted from 16 various kinds of Chinese traditional herbal medicines including Salvia miltiorrhiza, Angelica sinennsis, Astragali Radix, is clinically effective in treating atherosclerosisrelated diseases. Here, we tested the hypothesis that the anti-atherosclerosis effects of NXT might be mediated by suppressing maturation of dendritic cells (DCs) in a mice model of atherosclerosis. LDLR-/- mice fed a high-fat diet were treated with placebo, NXT (0.7g/kg/d, oral diet) or simvastatin (100mg/kg/d, oral diet) for 8 weeks, respectively. NXT treatment significantly reduced plasma triglyceride (112±18 mg/dl vs. 192±68 mg/dl, P<0.05) and total cholesterol (944±158 mg/dl vs. 1387±208 mg/dl, P<0.05) compared to placebo treatment. Vascular lesions were significantly smaller and macrophage content and amount of DCs in plaques were significantly less in NXT and simvastatin groups than in placebo group (all P<0.05). In addition, expressions of splenic DC membrane molecules (CD40, CD86 and CD80) and the plasma level of IL-12p70 were significantly lower in NXT and simvastatin groups than in placebo group. In conclusion, NXT protects against atherosclerosis through lipid-lowering and inhibiting DCs maturation in this mice model of atherosclerosis.
Keywords: Atherosclerosis, naoxintong, dendritic cell.
Current Pharmaceutical Design
Title:Naoxintong Protects against Atherosclerosis through Lipid-lowering and Inhibiting Maturation of Dendritic Cells in LDL Receptor Knockout Mice fed a High-fat Diet
Volume: 19 Issue: 33
Author(s): Xueting Jin, Junbo Ge, Aijun Sun, Kai Hu, Yunzeng Zou, Keqiang Wang, Lifu Jia, Tao Zhao, Buchang Zhao, Jingjing Zhao, Shuxia Fan, Hangtian Zhao, Cong Wang, Xiangwei Liu, Xin Ma, Shijun Wang and Hong Zhu
Affiliation:
Keywords: Atherosclerosis, naoxintong, dendritic cell.
Abstract: Naoxintong (NXT), a Chinese Materia Medica standardized product, extracted from 16 various kinds of Chinese traditional herbal medicines including Salvia miltiorrhiza, Angelica sinennsis, Astragali Radix, is clinically effective in treating atherosclerosisrelated diseases. Here, we tested the hypothesis that the anti-atherosclerosis effects of NXT might be mediated by suppressing maturation of dendritic cells (DCs) in a mice model of atherosclerosis. LDLR-/- mice fed a high-fat diet were treated with placebo, NXT (0.7g/kg/d, oral diet) or simvastatin (100mg/kg/d, oral diet) for 8 weeks, respectively. NXT treatment significantly reduced plasma triglyceride (112±18 mg/dl vs. 192±68 mg/dl, P<0.05) and total cholesterol (944±158 mg/dl vs. 1387±208 mg/dl, P<0.05) compared to placebo treatment. Vascular lesions were significantly smaller and macrophage content and amount of DCs in plaques were significantly less in NXT and simvastatin groups than in placebo group (all P<0.05). In addition, expressions of splenic DC membrane molecules (CD40, CD86 and CD80) and the plasma level of IL-12p70 were significantly lower in NXT and simvastatin groups than in placebo group. In conclusion, NXT protects against atherosclerosis through lipid-lowering and inhibiting DCs maturation in this mice model of atherosclerosis.
Export Options
About this article
Cite this article as:
Jin Xueting, Ge Junbo, Sun Aijun, Hu Kai, Zou Yunzeng, Wang Keqiang, Jia Lifu, Zhao Tao, Zhao Buchang, Zhao Jingjing, Fan Shuxia, Zhao Hangtian, Wang Cong, Liu Xiangwei, Ma Xin, Wang Shijun and Zhu Hong, Naoxintong Protects against Atherosclerosis through Lipid-lowering and Inhibiting Maturation of Dendritic Cells in LDL Receptor Knockout Mice fed a High-fat Diet, Current Pharmaceutical Design 2013; 19 (33) . https://dx.doi.org/10.2174/1381612811319330008
DOI https://dx.doi.org/10.2174/1381612811319330008 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Congenital Blood Coagulation Factor XIII Deficiency and Perinatal Management
Current Drug Targets Renal Ischemia: How Commonly Does it Cause Renal Failure?
Current Hypertension Reviews Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design Inflammation Theories in Psychotic Disorders: A Critical Review
Infectious Disorders - Drug Targets Indications for Surgery and Operative Techniques in Infective Endocarditis in the Present Day
Infectious Disorders - Drug Targets Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Cardiovascular Physiology of Androgens and Androgen Testosterone Therapy in Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Inflammation, Adipocytokines, and Atherosclerosis in the Metabolic Syndrome
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Endothelial Therapy of Atherosclerosis and its Risk Factors
Current Vascular Pharmacology Future Perspectives on the Fibrinolytic Therapy of Intracerebral Hemorrhages
Central Nervous System Agents in Medicinal Chemistry The Role of Inflammation and Allergy in Acute Coronary Syndromes
Inflammation & Allergy - Drug Targets (Discontinued) Matrix Metalloproteinases
Current Medicinal Chemistry Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Early Hematoma Enlargement in Primary Intracerebral Hemorrhage
Current Drug Targets Olive Oil and Haemostasis: Platelet Function, Thrombogenesis and Fibrinolysis
Current Pharmaceutical Design Animal Models for Studying Neointima Formation
Current Vascular Pharmacology Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Cell-free Nucleic Acids as a Non-Invasive Route for Investigating Atherosclerosis
Current Pharmaceutical Design